Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dextromethorphan Polistirex

FDA-approved product (suspension, extended release, oral), marketed as Delsym, Dextromethorphan Polistirex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dextromethorphan Polistirex
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Common cold
  • Cough
  • Fever
  • Headache
  • Nasal congestion
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other nervous system drugs; Opium alkaloids and derivatives
FDA pharmacologic class
Sigma-1 Agonist; Uncompetitive N-methyl-D-aspartate Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dextromethorphan Polistirex in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dextromethorphan Polistirex with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dextromethorphan in Treating Patients With Fatigue Caused by Cancer

    NCT00176540 · start 2003-10

    Registered record
    Registry ID
    NCT00176540
    Conditions
    Fatigue; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    dextromethorphan hydrobromide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2003-10
    Completion
    2007-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFatigue; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
    Interventiondextromethorphan hydrobromide
    PhaseNot applicable
    Registry statusTerminated

  • Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

    NCT00056524 · start 2003-02

    Registered record
    Registry ID
    NCT00056524
    Conditions
    Alzheimer's Disease; Stroke; Parkinson's Disease; Traumatic Brain Injury
    Interventions
    AVP-923
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-02
    Completion
    2007-06
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Stroke; Parkinson's Disease; Traumatic Brain Injury
    InterventionAVP-923
    PhasePhase 3
    Registry statusCompleted

  • rhGH Therapy on Hepatic Drug Metabolism

    NCT00458991 · start 2001-06

    Registered record
    Registry ID
    NCT00458991
    Conditions
    Growth Hormone Deficiency, Dwarfism
    Interventions
    Dextromethorphan and Caffeine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-06
    Completion
    2008-09
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrowth Hormone Deficiency, Dwarfism
    InterventionDextromethorphan and Caffeine
    PhaseNot recorded
    Registry statusCompleted

  • Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain

    NCT00001725 · start 1997-12

    Registered record
    Registry ID
    NCT00001725
    Conditions
    Facial Neuralgia; Pain; Trigeminal Neuralgia
    Interventions
    Dextromethorphan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-12
    Completion
    2002-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFacial Neuralgia; Pain; Trigeminal Neuralgia
    InterventionDextromethorphan
    PhasePhase 2
    Registry statusCompleted

  • Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1

    NCT00000352 · start 1996-12

    Registered record
    Registry ID
    NCT00000352
    Conditions
    Opioid-Related Disorders; Substance-Related Disorders
    Interventions
    Dextromethorphan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-12
    Completion
    1998-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders; Substance-Related Disorders
    InterventionDextromethorphan
    PhasePhase 2
    Registry statusCompleted